Immediate and Mid-term Effect of a Natural Topical Product in Patients With Musculoskeletal Pain

Sponsor
Uriach Consumer Healthcare (Industry)
Overall Status
Completed
CT.gov ID
NCT04683263
Collaborator
Quironsalud (Other)
200
1
2
6.6
30.1

Study Details

Study Description

Brief Summary

Musculoskeletal pain is a common affection due to ageing, sedentarism and intense exercise practice causing acute and chronic injuries.

The main objective of this trial is to prove efficacy of a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol in pain management in adults with acute or chronic pain.

This randomized, double-blinded and placebo-controlled trial will include 200 patients with musculoskeletal pain, 100 in the intervention group receiving the topical formula and 100 in the placebo group, who will receive a similar formula without active ingredients.

The products will be applied topically twice daily for 14 days in areas with moderate or severe pain.

The study objectives are immediate and long-term pain alleviation, stiffness perception joint mobility, and general recovery perception.

Condition or Disease Intervention/Treatment Phase
  • Other: Placebo
  • Other: Fisiocrem
N/A

Detailed Description

Well-being is understood as the absence of limitations or debilitating conditions that make impossible to enjoy a full and satisfactory life. Among these limitations, a reduced or impaired motility because of painful and inflammatory processes (acute and chronic), can greatly disturb a vital and optimistic attitude.

Chronic pain affects between one-third and one-half of the population only in the UK, and around 20.4% in the US. It is likely to increase with population ageing and tends to be more common in women. Ageing is translated in an increase in the incidence and span of chronic illnesses, including osteoarthritis, fibromyalgia, lower back pain, non-arthritis joint pain or carpal tunnel syndrome, among others. In addition, muscular and joints pain unrelated to any specific disease also tends to appear with age. Beyond that, current lifestyle frequently involves stressful jobs, eventful agendas and non-stop activity either in professional or leisure time. These facts extend the prevalence of chronic pain to younger segments of the population and to people not affected by previous disease.

Sedentary lifestyle and computer-based jobs represent a common cause of muscular contractures and pain, especially in the back and neck areas. Another important contributor to chronic pain is perceived stress and anxiety response systems. As an emergent antagonist phenomenon, increasing awareness of a healthy lifestyle has entailed a rise in the popularity of physical exercise in the last decades. As an example, the number of running events finishers in the U.S. stabilized in 2014 at almost 20 million people, with figures having been on the rise for the previous 25 years. The popularization of exercise programs such as CrossFit illustrate that the trend is directed not only towards a rise in practice, but also in intensity. Thus, the increase in the practice of high-intensity physical activity and the alternation between sedentary and exercise periods involve an increase in inflammatory and acute painful episodes, being tendinitis and joint lesions the major problem, followed by sprains or bruises.

The pharmacological management of these conditions involves nonsteroidal anti-inflammatory drugs (NSAIDs), local corticosteroids, acetaminophen, chondroitin sulfate or even opioids. These are effective drugs but with serious side effects in some cases, especially in the long-term utilization. Severe drawbacks related to the prolonged utilization of these drugs include drug ineffectiveness, toxicity of certain agents, hypersensitivity, gastrointestinal hemorrhage, nauseas and even fatal outcomes including death and suicide. Importantly, increased abuse of painkillers has been reported in several countries, exceeding tobacco consumption and being considered a public health problem. Furthermore, the use of painkillers should be avoided in sensitive population groups including children and pregnant women, who are equally exposed to sustained or acute pain episodes.

Alternative solutions of greater safety but equivalent rapid relief and recovery effectiveness are a necessity. In this sense, the most useful approach are natural products, without tolerability concerns, compatible with other interventions and providing a rapid effect. These generalize access to effective treatment to both patients and physiotherapy professionals. Considering the well-established beneficial effects of physiotherapy in handling chronic pain, professionals need effective and safe solutions that they can use without concerns of side effects or pharmacological interactions, since they may not have access to the full medical record of the patients. In turn, the ability of handling self-treatment without concern increases the quality of life in patients suffering from pain-involving conditions.

This study evaluates the use of a topical cream composed by natural extracts with complementary and synergistic effects for pain management. Menthol reduces pain and increases blood flow, warming up the muscle and enhancing absorption of the rest of the extracts. Arnica montana reduces pain, has anti-inflammatory effects and potentiates tissue repair. Hypericum perforatum provides anti-inflammatory effect and drives tissue regeneration and scarring. Calendula officinalis reduces swelling and distension, boosts healing of mild injuries and prevents infection. Finally, Melaleuca alternifolia complements the anti-inflammatory effect and acts as a natural preservative due to its potent antimicrobial effect.

The synergistic combination of these natural ingredients may provide a convenient solution for the management acute or chronic pain. The aim of this study is to assess the benefits of the topical formulation in reducing musculoskeletal pain, both as an immediate relief of pain and as a solution for injury recovery.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, randomized, double-blinded and placebo-controlled clinical trialProspective, randomized, double-blinded and placebo-controlled clinical trial
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
Patients were randomly assigned, using the Excel (Microsoft) RAND function, into 2 groups: treatment group and placebo group, a topical cream with similar characteristics and aspect, without active ingredients. Allocation was concealed from the recruiter and participants.
Primary Purpose:
Treatment
Official Title:
Immediate and Mid-term Effect of a Natural Topical Product in Patients With Musculoskeletal Pain: a Randomized, Double-blinded, and Placebo-controlled Clinical Trial.
Actual Study Start Date :
Jun 1, 2019
Actual Primary Completion Date :
Dec 20, 2019
Actual Study Completion Date :
Dec 20, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Intervention

Fisiocrem®, a topical cream composed of the natural ingredients Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol

Other: Fisiocrem
a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol

Placebo Comparator: Placebo

topical cream with similar characteristics and aspect, without active ingredients.

Other: Placebo
topical cream with same composition as Intervention but without active ingredients

Outcome Measures

Primary Outcome Measures

  1. Average variation in pain at rest [14 days (0, 7 and 14 days)]

    pain reduction after intervention measured as per a Visual Analog Scale (1 - 10, higher values indicating more pain)

  2. Average variation in pain in motion [14 days (0, 7 and 14 days)]

    pain reduction after intervention measured as per a Visual Analog Scale (1 - 10, higher values indicating more pain)

Secondary Outcome Measures

  1. Average variation in pain at rest [2 hours (0, 30 minutes, 1 hour, 2 hours)]

    pain reduction after intervention measured as per a Faces Scale (1 - 10, higher values indicating more pain)

  2. Average variation in pain in motion [2 hours (0, 30 minutes, 1 hour, 2 hours)]

    pain reduction after intervention measured as per a Faces Scale (1 - 10, higher values indicating more pain)

  3. Average variation in stiffness at rest [2 hours (0, 30 minutes, 1 hour, 2 hours)]

    stifness reduction after intervention measured as per a Stifness scale - (0) no stiffness, (1) slight stiffness, (2) moderate stiffness and (3) severe stiffness.

  4. Average variation in stiffness in motion [2 hours (0, 30 minutes, 1 hour, 2 hours)]

    stifness reduction after intervention measured as per a Stifness scale - (0) no stiffness, (1) slight stiffness, (2) moderate stiffness and (3) severe stiffness.

  5. Average variation in stiffness at rest [14 days (0, 7 and 14 days)]

    stifness reduction after intervention measured as per a Stifness scale -- (0) no stiffness, (1) slight stiffness, (2) moderate stiffness and (3) severe stiffness.

  6. Average variation in stiffness in motion [14 days (0, 7 and 14 days)]

    stifness reduction after intervention measured as per a Stifness scale - (0) no stiffness, (1) slight stiffness, (2) moderate stiffness and (3) severe stiffness.

  7. Recovery perception [14 days (0, 7 and 14 days)]

    Subjective perception of recovery as per a Likert scale ((1) meant fully recovered, (2) much better, (3) better, (4) same as before and (5) worse than before.)

  8. Joint mobility [14 days (0, 7 and 14 days)]

    Joint mobility evaluation as per passive joint balance ((1) free mobility, (2) partial limitation, (3) moderate limitation and (4) severe limitation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • acute or chronic musculoskeletal pain scoring above 4 in the Visual Analogue Scale (VAS)

  • diagnostic of either tendinopathy, vertebral algias, sprains or symptomatic osteoarthritis

Exclusion Criteria:
  • diagnostic in either neuropathic chronic pain, fibromyalgia or neoplasia

  • allergy to any ingredient in the formula

Contacts and Locations

Locations

Site City State Country Postal Code
1 QuironSalud Hosiptal Barcelona Spain 08023

Sponsors and Collaborators

  • Uriach Consumer Healthcare
  • Quironsalud

Investigators

  • Principal Investigator: Silvia Ramon, MD, PhD, Hospital QuiroSalud Barcelona

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Uriach Consumer Healthcare
ClinicalTrials.gov Identifier:
NCT04683263
Other Study ID Numbers:
  • 07CRT_VV_323_18-003
First Posted:
Dec 24, 2020
Last Update Posted:
Feb 8, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Uriach Consumer Healthcare
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2021